This discrepancy is not shared with other dopamine reuptake inhbitors like bupropion, sibutramine, mazindol or tesofensine, which have very similar or increased potencies than copyright as dopamine reuptake inhibitors. These results have evoked a speculation that copyright may operate as a so-identified as "DAT inverse agonist" or "unfavorable allosteric modifier https://rodneyz333aui4.theisblog.com/profile